Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer

Clinical Colorectal Cancer

Volumn 11, Issue 2, 2012, Pages 101-111

  Saltz, Leonard ^a   Badarinath, Suprith ^b   Dakhil, Shaker ^c   Bienvenu, Bryan ^d   Harker, W Graydon ^e   Birchfield, George ^f,g   Tokaz, Laurence K ^f,h   Barrera, David ^f,h   Conkling, Paul R ^f,i   O'Rourke, Mark A ^f,j   Richards, Donald A ^f,h   Reidy, Diane ^a   Solit, David ^a   Vakiani, Efsevia ^a   Capanu, Marinella ^a   Scales, Amy ^f   Zhan, Feng ^f   Boehm, Kristi A ^f   Asmar, Lina ^f   Cohn, Allen ^f,k  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b North Florida Hematology and Oncology Associates   (United States)

^c Cancer Center of Kansas   (United States)

^d Louisiana Hematology Oncology Associates   (United States)

^e Utah Cancer Specialists   (United States)

^f US Oncology Research   (United States)

^g Puget Sound Cancer Centers   (United States)

^h TEXAS ONCOLOGY   (United States)

ⁱ Virginia Oncology Associates   (United States)

^j Cancer Centers of the Carolinas   (United States)

^k ROCKY MOUNTAIN CANCER CENTERS   (United States)

more..

Author keywords

cetuximab; Colorectal cancer; KRAS; oxaliplatin

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ACNE; ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DISEASE CONTROL; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; NEUTROPENIA; ONCOGENE K RAS; OVERALL SURVIVAL; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; VEIN THROMBOSIS; VOMITING;

EID: 84860785653     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2011.05.006     Document Type: Article

References (15)

1. M.T. Seymour, T.S. Maughan, J.A. Ledermann Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomized controlled trial Lancet 370 2007 143 152 (Pubitemid 47042894)
2. M. Koopman, N.F. Antonini, J. Douma Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial Lancet 370 2007 135 142 (Pubitemid 47042893)
3. L.B. Saltz, H.J. Lenz, H.L. Kindler Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study J Clin Oncol 25 2007 4557 4561 (Pubitemid 350035312)
4. The Criteria Committee of the New York Heart Association Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels 9th ed. 1994 Little, Brown & Co Boston, MA 253 256
5. P. Therasse, S.G. Arbuck, E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
6. Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events v3.0 (CTCAE) http://www.ctep.cancer.gov/protocolDevelopment/electronic- applications/ctc.htm Accessed June 6, 2011
7. K. Yost, E. Hahn, D. Cella A new measure of chemotherapy convenience and satisfaction: the CCSQ J Clin Oncol 23 2005 538s
8. E.L. Kaplan, P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
9. L. Saltz, M. Rubin, H. Hochster Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR) Proc Am Soc Clin Oncol 20 2001 abstract 7
10. D. Cunningham, Y. Humblet, S. Siena Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337 345 (Pubitemid 38944402)
11. E. Van Cutsem, C.H. Köhne, E. Hitre Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 2009 1408 1417
12. E. Van Cutsem, C.H. Köhne, I. Láng Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status J Clin Oncol 29 2011 2011 2019
13. J. Tol, M. Koopman, A. Cats Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer N Engl J Med 360 2009 563 572
14. J.R. Hecht, E. Mitchell, T. Chidiac Randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer J Clin Oncol 27 2009 672 680
15. C. Bokemeyer, I. Bondarenko, A. Makhson et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 2009 663 671